

Bradley G Hammill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2581165/publications.pdf>

Version: 2024-02-01

69
papers

3,305
citations

218677

26
h-index

149698

56
g-index

70
all docs

70
docs citations

70
times ranked

4900
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence and Prevalence of Atrial Fibrillation and Associated Mortality Among Medicare Beneficiaries: 1993–2007. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 85-93.	2.2	476
2	Relationship Between Cardiac Rehabilitation and Long-Term Risks of Death and Myocardial Infarction Among Elderly Medicare Beneficiaries. <i>Circulation</i> , 2010, 121, 63-70.	1.6	438
3	Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. <i>American Heart Journal</i> , 2009, 157, 995-1000.	2.7	344
4	Impact of Heart Failure on Patients Undergoing Major Noncardiac Surgery. <i>Anesthesiology</i> , 2008, 108, 559-567.	2.5	265
5	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021, 384, 1981-1990.	27.0	145
6	Outcomes of Medicare Beneficiaries Undergoing Catheter Ablation for Atrial Fibrillation. <i>Circulation</i> , 2012, 126, 2200-2207.	1.6	138
7	Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 305-309.	4.1	101
8	Incremental Value of Clinical Data Beyond Claims Data in Predicting 30-Day Outcomes After Heart Failure Hospitalization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 60-67.	2.2	96
9	Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. <i>American Heart Journal</i> , 2013, 165, 979-986.e1.	2.7	74
10	Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study. <i>Statistics in Medicine</i> , 2016, 35, 4824-4836.	1.6	73
11	Home-Time After Discharge Among Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2643-2652.	2.8	72
12	Rationale and Design of the Aspirin Dosing—A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. <i>JAMA Cardiology</i> , 2020, 5, 598.	6.1	59
13	Trends in the Use and Outcomes of Ventricular Assist Devices Among Medicare Beneficiaries, 2006 Through 2011. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1395-1404.	2.8	56
14	Anti-VEGF Treatment Patterns for Neovascular Age-Related Macular Degeneration Among Medicare Beneficiaries. <i>American Journal of Ophthalmology</i> , 2014, 158, 537-543.e2.	3.3	55
15	Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1973.	7.4	53
16	Outcomes of Medicare Beneficiaries With Heart Failure and Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2014, 2, 41-48.	4.1	52
17	In-Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization. <i>Journal of the American Heart Association</i> , 2014, 3, .	3.7	48
18	Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 793-799.	4.8	45

#	ARTICLE	IF	CITATIONS
19	Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2209.	7.4	35
20	Hospital and clinical care costs associated with atrial fibrillation for Medicare beneficiaries in the Cardiovascular Health Study and the Framingham Heart Study. <i>SAGE Open Medicine</i> , 2018, 6, 205031211875944.	1.8	35
21	Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS. <i>Journal of Cardiac Failure</i> , 2016, 22, 672-679.	1.7	34
22	Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 9-17.	1.9	34
23	Long-term Outcomes Among Elderly Survivors of Out-of-Hospital Cardiac Arrest. <i>Journal of the American Heart Association</i> , 2016, 5, e002924.	3.7	31
24	Associations Between Use of the Hospitalist Model and Quality of Care and Outcomes of Older Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 445-453.	4.1	30
25	Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 826-836.	1.7	30
26	The Burden of Congestion in Patients Hospitalized With Acute Decompensated Heart Failure. <i>American Journal of Cardiology</i> , 2019, 124, 545-553.	1.6	29
27	Discharge heart rate and β -blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. <i>American Heart Journal</i> , 2016, 173, 172-178.	2.7	28
28	Hospital Resource Utilization Before and After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1135-1146.	2.8	26
29	Significant Morbidity and Mortality Among Hospitalized End-Stage Liver Disease Patients in Medicare. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 412-419.e1.	1.2	25
30	Prescriber Continuity and Disease Control of Older Adults. <i>Medical Care</i> , 2017, 55, 405-410.	2.4	23
31	Measuring the burden of multimorbidity among Medicare beneficiaries via condition counts and cumulative duration. <i>Health Services Research</i> , 2019, 54, 484-491.	2.0	23
32	Clinical Effectiveness of Cardiac Resynchronization Therapy Versus Medical Therapy Alone Among Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 926-934.	3.9	20
33	Adherence and Persistence in the Use of Warfarin After Hospital Discharge Among Patients With Heart Failure and Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2014, 20, 23-30.	1.7	20
34	Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	19
35	Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006292.	2.2	19
36	Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	18

#	ARTICLE	IF	CITATIONS
37	Use and 1-year outcomes with conventional and drug-coated balloon angioplasty in patients with lower extremity peripheral artery disease. <i>American Heart Journal</i> , 2019, 217, 42-51.	2.7	16
38	Linkage of Laboratory Results to Medicare Fee-for-Service Claims. <i>Medical Care</i> , 2015, 53, 974-979.	2.4	15
39	Cardiovascular events and hospital resource utilization pre- and post-transcatheter mitral valve repair in high-surgical risk patients. <i>American Heart Journal</i> , 2017, 189, 146-157.	2.7	15
40	Characteristics of Acute Heart Failure Hospitalizations Based on Presenting Severity. <i>Circulation: Heart Failure</i> , 2019, 12, e005171.	3.9	15
41	Use of Medicare Claims to Identify Adverse Clinical Outcomes After Mitral Valve Repair. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007451.	3.9	15
42	Association of Implantable Device Measured Physical Activity With Hospitalization for Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 280-288.	4.1	15
43	Regional Adiposity and Risk of Heart Failure and Mortality: The Jackson Heart Study. <i>Journal of the American Heart Association</i> , 2021, 10, e020920.	3.7	14
44	COSTS OF NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMONG MEDICARE BENEFICIARIES, 2004-2008. <i>Retina</i> , 2013, 33, 854-861.	1.7	11
45	Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e021459.	3.7	10
46	Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, CIRCOUTCOMES121008190.	2.2	9
47	Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. <i>American Heart Journal</i> , 2015, 170, 1124-1132.	2.7	8
48	Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. <i>American Heart Journal</i> , 2018, 200, 134-140.	2.7	8
49	Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations. <i>American Heart Journal</i> , 2020, 226, 13-23.	2.7	7
50	Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). <i>American Journal of Cardiology</i> , 2020, 125, 1655-1660.	1.6	7
51	Evaluating fitness-for-use of electronic health records in pragmatic clinical trials: reported practices and recommendations. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2022, 29, 798-804.	4.4	7
52	Prescriber continuity and medication availability in older adults with cardiometabolic conditions. <i>SAGE Open Medicine</i> , 2018, 6, 205031211875738.	1.8	6
53	Early Increased Physical Activity, Cardiac Rehabilitation, and Survival After Implantable Cardioverter-Defibrillator Implantation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007580.	2.2	6
54	Associations Between Anticoagulation Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 670-679.	2.2	5

#	ARTICLE	IF	CITATIONS
55	Cost Analysis of Periprocedural Imaging in Patients Undergoing Catheter Ablation for Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2014, 114, 266-271.	1.6	5
56	Considerations for using distributed research networks to conduct aspects of randomized trials. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100515.	1.1	5
57	Relationship Between HCAHPS Scores and Survey Response Rate Is Linked to Hospital Size. <i>Journal of Patient Experience</i> , 2020, 7, 1543-1548.	0.9	5
58	Performance of propensity score methods when comparison groups originate from different data sources. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 81-89.	1.9	4
59	Association of Practice-Level Hospital Use With End-of-Life Outcomes, Readmission, and Weekend Hospitalization Among Medicare Beneficiaries With Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, e933-e943.	2.5	4
60	Disproportionate Use of Inpatient Care by Older Adults With Kidney Stones. <i>Urology</i> , 2018, 120, 103-108.	1.0	4
61	Selection Bias in Observational Studies of Palliative Care: Lessons Learned. <i>Journal of Pain and Symptom Management</i> , 2021, 61, 1002-1011.e2.	1.2	4
62	Life expectancy and voting patterns in the 2020 U.S. presidential election. <i>SSM - Population Health</i> , 2021, 15, 100840.	2.7	4
63	Effectiveness of implantable cardioverter-defibrillators in survivors of in-hospital cardiac arrest. <i>American Heart Journal</i> , 2015, 169, 870-878.e1.	2.7	3
64	Medicaid Coverage Disruptions Among Children Enrolled in North Carolina Medicaid From 2016 to 2018. <i>JAMA Health Forum</i> , 2021, 2, e214283.	2.2	3
65	Appropriate baseline laboratory testing following ACEI or ARB initiation by Medicare FFS beneficiaries. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1015-1022.	1.9	2
66	Care continuity impacts medicare expenditures of older adults: Fact or fiction?. <i>Healthcare</i> , 2020, 8, 100364.	1.3	2
67	Few Disparities in Baseline Laboratory Testing After the Diuretic or Digoxin Initiation by Medicare Fee-For-Service Beneficiaries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 714-722.	2.2	1
68	Frequency of Disparities in Laboratory Testing After Statin Initiation in Subjects ≥ 65 Years. <i>American Journal of Cardiology</i> , 2016, 118, 376-382.	1.6	1
69	Linking a Total Ankle Arthroplasty Registry to Medicare Inpatient Claims without Unique Identifiers. <i>Journal of Bone and Joint Surgery - Series A</i> , 2018, 100, 1016-1022.	3.0	0